Please login to the form below
interferon beta-1a
This page shows the latest interferon beta-1a news and features for those working in and with pharma, biotech and healthcare.
Ocrevus off to a flying start as Roche raises 2017 forecasts
The take-up of the drug has been buoyed by trials showing that the drug outperformed Merck KGaA's MS stalwart Rebif (interferon beta-1a) in two relapsing MS phase III
Latest news
-
Roche sets disruptive price for new MS drug Ocrevus in US
Ocrevus' clinical profile has already caught the attention of MS patients and their doctors, with trials showing that the drug outperformed Merck KGaA's Rebif (interferon beta-1a) in two relapsing
-
Avelumab costs peg back profit at Merck KGaA
Pfizer-partnered avelumab is central to Merck's plans to revitalise its healthcare business, currently under pressure as top-selling Rebif (interferon beta-1a) - an injectable treatment for multiple sclerosis - tries
-
FDA delays verdict on Roche's MS drug Ocrevus
Ocrevus is the first investigational medicine with the potential to treat both forms, outperforming Merck KGaA's Rebif (interferon beta-1a) in the two relapsing multiple sclerosis phase III trials and
-
Merck's pharma unit faces tougher 2017 as fertility boost recedes
2017". That's important because Gonal-f has buoyed Merck's healthcare unit in the face of declining sales for its two biggest products - injectable multiple sclerosis therapy Rebif (interferon ... 1a) and colorectal cancer therapy Erbitux (cetuximab) -
-
Fertility drugs drive healthcare growth at Merck KGaA
Merck makes the most of its portfolio of mature drugs, and top-seller Rebif (interferon beta-1a) for relapsing-remitting multiple sclerosis held up fairly well despite fierce competition from newer,
More from news
Approximately 1 fully matching, plus 50 partially matching documents found.
Latest Intelligence
-
Tackling a formidable foe
Formidable foe. “With Rebif (interferon beta-1a), Merck’s legacy MS therapy approved in Europe 20 years ago, one of the innovations is the ability to have auto-injectors and devices
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
-
Account Director
-
Competitive Salary Offered
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Director, Medical Education
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Manager / Account Director
-
Competative
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
-
Senior Account Manager
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
Subscribe to our email news alerts
- Meet Porterhouse Medical at the ISMPP EU meeting 2019 in London 22 - 23 January
- Immunomedics craters after FDA rejects breast cancer ADC
- UK businesses leaning towards second Brexit vote
- NHS England sees off AbbVie's Hep C legal challenge
- China’s clinical trial shake-up
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
PMHub
infill healthcare communication
infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...
Latest intelligence
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
Quick links
Infographics
